Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer vaccines

D M Pardoll1

  • 1Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.

Immunology Today
|June 1, 1993
PubMed
Summary
This summary is machine-generated.

Cancer immunotherapy, pioneered by William Coley, shows promise but isn't standard therapy. Newer molecular vaccines and defining tumor antigens may lead to effective, targeted cancer vaccines.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis.

Mucosal immunology·2016
Same author

Comparative analysis of paracrine immunotherapy in experimental brain tumors.

Neurosurgical focus·2006
Same author

Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines.

Vaccine·2002
Same author

Immunology. Stress, NK receptors, and immune surveillance.

Science (New York, N.Y.)·2001
Same author

Antigen-specific blockade of T cells in vivo using dimeric MHC peptide.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same journal

Foreword.

Immunology today·2020
Same journal

The origin and significance of anti-DNA antibodies.

Immunology today·2014
Same journal

Mutations of class II MHC molecules.

Immunology today·2014
Same journal

Antigen processing at the molecular level.

Immunology today·2014
Same journal

Phenotypically and functionally distinct T-cell subsets in anti-tumor responses.

Immunology today·2014
Same journal

Are MHC class II-restricted cytotoxic T lymphocytes important?

Immunology today·2014
See all related articles

Area of Science:

  • Immunology
  • Oncology
  • Vaccine Development

Background:

  • William Coley's 1893 report marked the 100th anniversary of early cancer immunotherapy using bacterial toxins.
  • Despite early promise, active immunotherapy has not become a standard cancer treatment modality.
  • Cancer vaccines have historically yielded mixed results in clinical trials.

Purpose of the Study:

  • To review the historical context and current state of cancer immunotherapy.
  • To highlight advancements in molecular vaccine approaches.
  • To discuss the future potential of antigen-specific cancer vaccines.

Main Methods:

  • Historical review of cancer immunotherapy research.
  • Analysis of recent advancements in molecular vaccine design.

Related Experiment Videos

  • Discussion of the role of tumor-specific antigens in vaccine development.

    • Main Results:

    • Early immunotherapy showed tumor regressions but lacked consistent efficacy.
    • Modern molecular vaccine strategies demonstrate improved systemic antitumor effects in preclinical models.
    • Identification of tumor-specific antigens is crucial for targeted vaccine development.

    Conclusions:

    • Active immunotherapy remains a developing field in cancer treatment.
    • Molecular vaccine approaches offer a rational path toward more effective cancer therapies.
    • Targeted, antigen-specific vaccines hold significant future potential for cancer treatment.